Publications by authors named "Jan Bubenik"

Claim this Profile
U
Utilization of Alternative Fibres Manufactured from Recycled PET Bottles in Concrete Technology for the Improvement of Fire Resistance.
Martin Sedlmajer, Jiří Zach, Jan Bubeník, Jiří Bydžovský, Vítězslav Novák

Polymers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.
Jana Simova, Olena Sapega, Terezie Imrichova, Ivan Stepanek, Lenka Kyjacova, Jan Bubenik

Oncotarget· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rodney A Rosalia, Ivan Štěpánek, Veronika Polláková, Jana Šímová, Jana Bieblová

Immunobiology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine.
Romana Mikyšková, Marie Indrová, Jana Símová, Jana Bieblová, Jan Bubeník

Oncol Rep· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours.
Marie Indrová, Jana Símová, Jana Bieblová, Jan Bubeník, Milan Reinis

Oncol Rep· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.
Jana Símová, Marie Indrová, Jana Bieblová, Romana Mikysková, Jan Bubeník

Int J Cancer· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines.
Milan Reinis, Ivan Stepanek, Jana Simova, Jana Bieblova, Hana Pribylova, Jan Bubenik

Int J Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
Marie Indrová, Jana Bieblová, Joana Rossowska, Piotr Kuropka, Elzbieta Pajtasz-Piasecka

Int J Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours.
Jasper Manning, Marie Indrova, Barbora Lubyova, Hana Pribylova, Jana Bieblova, Jan Bubenik

Immunology· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets.
Marie Indrová, Jana Bieblová, Jan Bubeník, Milan Reinis

Int J Oncol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
Milan Reinis, Jana Símová, Marie Indrová, Jana Bieblová, Jan Bubeník

Int J Oncol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.
Milan Reinis, Jana Símová, Marie Indrová, Jana Bieblová, Hana Pribylová

Int J Oncol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
Jana Símová, Jan Bubeník, Jana Bieblová, Rodney Alexander Rosalia, Jan Fric

Int J Oncol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours.
Milan Reinis, Jana Símová, Jan Bubeník

Int J Cancer· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease as the target for immunotherapy and gene therapy of cancer (review).
Jan Bubeník, Jana Símová

Oncol Rep· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Romana Mikysková, Jan Bubeník, Vladimír Vonka, Michal Smahel, Marie Indrova

Int J Oncol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Milan Reinis, Marie Indrová, Luis Mendoza, Romana Mikysková, Jana Bieblová

Int J Oncol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MHC class I down-regulation: tumour escape from immune surveillance? (review).
Jan Bubeník

Int J Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour MHC class I downregulation and immunotherapy (Review).
Jan Bubeník

Oncol Rep· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Romana Mikysková, Marie Indrová, Jana Símová, Tána Jandlová, Jana Bieblová

Int J Oncol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MHC class I status of tumours and design of immunotherapeutic strategies.
Jan Bubeník, Vladimír Vonka

Immunol Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Marie Indrová, Jan Bubeník, Romana Mikysková, Luis Mendoza, Jana Símová

Int J Oncol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16.
Jan Bubeník, Romana Mikysková, Vladimír Vonka, Luis Mendoza, Jana Símová

Vaccine· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
Marie Indrová, Jan Bubeník, Romana Mikysková, Vladimír Vonka, Michal Smahel

Int J Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis